Quarterly report · Q1
6523.TEDINET S100OZNU
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥81.5bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥80.9bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥2.0bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥5.6bn | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥6.3bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥14.1bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥7.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥10.4bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥7.0bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥10.4bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥595.7bn | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥591.3bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥571.4bn | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥458.0bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥455.3bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥137.7bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥119.6bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥107.6bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥136.9bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥119.0bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥82.1bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥57.5bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥13.8bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥4.7bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥11.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥13.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-57.26 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥89.39 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-57.26 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥86.31 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 23.0% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 20.8% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | ¥552m |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-06-30 | ¥552m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥6.7bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥26.5bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥26.5bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥5.5bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥23.4bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥23.4bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥31.1bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥31.1bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.0bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥80.9bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥80.9bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥8.8bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | ¥940m |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-06-30 | ¥940m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥3.1bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥26.3bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥26.3bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥3.5bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥21.9bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥21.9bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥1.7bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥31.8bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥31.8bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥3.6bn |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥80.0bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥80.0bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥8.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 810
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | 552000000 | JPY |
| Revenue IFRS | CurrentYTDDuration | 81502000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember | 5485000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember | 2027000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 1244000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 8757000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -6710000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 2046000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 77000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 8421000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | -6297000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember | 2667000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember | 2711000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 1878000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReportableSegmentsMember | 7257000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReconcilingItemsMember | 188000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration | 7446000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember | 74000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReportableSegmentsMember | 74000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration | 74000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第10期第１四半期（自 2022年４月１日 至 2022年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ＰＨＣホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | PHC Holdings Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO 宮﨑 正次 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区西新橋二丁目38番５号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6695-9938 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務執行役員 最高財務責任者（CFO） フレデリック・ライデンバック | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区西新橋二丁目38番５号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6695-9938 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務執行役員 最高財務責任者（CFO） フレデリック・ライデンバック | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E36976 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 65230 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ＰＨＣホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | PHC Holdings Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |